期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

口服与静脉铁剂治疗肾性贫血的疗效比较

下载PDF
导出
摘要 目的对慢性肾功衰竭尿毒症患者口服及静脉补铁辅助治疗肾性贫血进行疗效比较。方法选择血液透析患者中病情相对稳定的患者共30人,平均分两组,一组给予口服补充铁剂(维铁缓释片)1片/d,第二组给予静脉补铁(蔗糖铁注射液)每次100mg,每周2次,共9周,依据治疗前后各项指标变化比较两种方法疗效[1]。结果第一组口服补铁有效率18%,并出现明显胃肠道副反应;第二组静脉补铁有效率75%,副作用少。结论慢性肾功衰竭尿毒症肾性贫血的患者静脉补铁优于口服补铁方法。
作者 邢颖
机构地区 辽宁省丹东市中心医院肾内科
出处 《中国现代药物应用》 2013年第4期F0003-F0003,共1页 Chinese Journal of Modern Drug Application
关键词 肾性贫血 血清铁缺乏 蔗糖铁 维铁缓释片 慢性肾功能衰竭
分类号 R692.5 [医药卫生—泌尿科学]
  • 相关文献

参考文献3

二级参考文献24

  • 1Roberts MA. Dialysis patients without known cardiovascular disease have high cardiovascular mortality: analysis of the Australia and New Zealand dialysis and transplant (ANZDATA) registry. Program and abstracts of the American Society of Nephrology 2006 Annual Meeting, San Diego, California. Washington DC: American Society of Nephrology, 2006.
  • 2Sommerer C, Beimler J, Schwenger V, et al. Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest, 2007,37:350-356.
  • 3Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med, 2005,353:238-248.
  • 4Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int, 2006,70:1318-1324.
  • 5Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin Ⅱ type- 1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant, 2006,21:2507- 2512.
  • 6Cice G, Ferrara L, D' Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol, 2003,41:1438-1444.
  • 7Shoji T, Tsubakihara Y, Fujii M, et al. Hemodialysisassociated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int, 2004,66: 1212-1220.
  • 8Sherman RA. Modifying the dialysis prescription to reduce intradialytic hypotension. Am J Kidney Dis, 2001,38 (4 Suppl 4):S18-S25.
  • 9Kilpatrick RD, DeRose cardiovascular mortality SF. Serum triglyceride and in maintenance hemodialysis patients. Program and abstrats of the American Society of Nephrology 2006 Annual Meeting, San Diego, California. Washington DC: American Society of Nephrology, 2006.
  • 10Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int, 2006,70:1858-1865.

共引文献29

中国现代药物应用
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部